BioSpace News Archive

FORE Biotherapeutics today announced the closing of its $75 million Series D financing.

Longboard Pharmaceuticals, Inc. today announced that it has completed enrollment of its Phase 1b/2a clinical trial, the PACIFIC Study, which is evaluating LP352, an oral, centrally acting 5-HT2C receptor superagonist, in 52 participants with Developmental and Epileptic Encephalopathies (DEEs).

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, announced that it has conditionally extended its distribution agreement with Ultra Pain Products, Inc. for the company’s PainShield® and PainShield Plus®.

Pulmatrix is currently enrolling patients in a Phase 2 study of PUR1900 in adults with ABPA and Asthma.

Orsini Specialty Pharmacy (“Orsini”), a leading independent specialty pharmacy focused on rare diseases and gene therapies, announced today that Regeneron Pharmaceuticals, Inc. (“Regeneron”) has chosen Orsini to be the exclusive specialty pharmacy partner for VEOPOZ™ (pozelimab-bbfg).

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and partner in a wide-range of leading-edge, proprietary diagnostic and medical device technologies

Nexcella, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) designation for NXC-201 for the treatment of a life-threatening form of blood cancer, multiple myeloma.

FYR Diagnostics , an emerging company developing liquid biopsy technologies for the diagnosis of cancer and neurodegenerative diseases, is pleased to welcome Dr. Niall Lennon and Dr. Ryan Walters to its Scientific Advisory Board (SAB).

When Stacey Ma was a little girl, her dream was to work with patients as a doctor.

Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for Versi ® HD with GuideMe Software, a completely reinvented self-guided interface for the company’s VersiHD chronic home hemodialysis.